Parallel BRCA sequencing 'ups chances of optimal treatment'

​​​​​​​Welsh researchers have compared the utility of different testing methods in management of ovarian cancer

Carrying out BRCA tumour and germline sequencing in parallel is likely to detect more pathogenic mutations and reduce treatment delay for women with ovarian cancer, a study shows.

ovary and fallopian tube

The findings will help women eligible for a poly ADP ribose polymerase inhibitor (PARPi) to get on to therapy sooner, the UK researchers say.

The study examined next generation sequencing results for 844 women in Wales with high-grade serous ovarian, fallopian tube or peritoneal cancer.